Skip to main content

Table 1 Decrease in antibody level 6 months after drug treatment stratified by age

From: Longitudinal analysis of antibody responses to trachoma antigens before and after mass drug administration

Age (years) N % pgp3 Ab + after 6 mos (CI) P-value N % CT694 Ab + after 6 mos (CI) P-value
   IgG 0.06    0.28
1 8 22.24 (4.24, 40.25) 0.01 8 36.89 (10.46, 63.32) 0.002
2 5 9.64 (−13.14, 32.41) 0.83 6 32.25 (1.73, 62.77) 0.03
3 14 4.94 (−8.67, 18.54) 0.91 15 18.36 (−0.94, 37.67) 0.07
4 22 9.07 (−1.79, 19.93) 0.15 23 15.59 (0.00, 31.18) 0.05
5 30 12.01 (2.72, 21.31) 0.005 28 16.40 (2.27, 30.53) 0.01
6 26 4.01 (−5.98, 14.00) 0.86 25 0.60 (−14.36, 15.55) 1.00
   IgA 0.003    0.0006
1 7 60.08 (31.36, 88.80) <0.0001 6 75.06 (40.00, 100.00) <0.0001
2 5 60.11 (26.12, 94.10) <0.0001 4 68.85 (25.90, 100.00) 0.0003
3 12 47.91 (25.97, 69.85) <0.0001 10 34.25 (7.08, 61.41) 0.01
4 14 41.91 (21.60, 62.22) <0.0001 11 30.93 (5.03, 56.83) 0.01
5 23 45.52 (29.67, 61.37) <0.0001 20 53.66 (34.45, 72.87) <0.0001
6 20 52.53 (35.53, 69.52) <0.0001 17 53.01 (32.17, 73.84) <0.0001
  1. Values show the mean percentage drop in antibody median fluorescence intensity-background (MFI-BG) for IgG (top section) and IgA (bottom) from baseline to 6 months after drug treatment in paired samples. 95% confident intervals are shown in parentheses. P values testing for a difference from zero (no change) of < 0.05 were considered significant. P values in bold test for an average difference from zero across all age groups.